Show Entire Article
This morning there's a plethora of stuff to blog about: the Takeda-Millennium deal, more commentary about Merck and Schering-Plough and the extent of the Vytorin/Zetia fallout, Genentech's biotech bellweather earnings after the closing bell today, just to name a few.
But since I was out of pocket yesterday at LaGuardia covering the American Airlines story, I've decided to follow up on the Pfizer Exubera lung cancer warning and what it means to MannKind .
MNKD is the only company still developing an inhalable form of diabetic insulin. After PFE pulled Exubera off the market last fall, NovoNordisk and Eli Lilly /Alkermes gave up on their similar experimental products, but MNKD is not throwing in the towel.
The California company put out a press release this morning saying that in mice, animals and people it has seen no evidence yet of carcinogenicity with its device. Nonetheless, in the wake of the Pfizer announcement yesterday morning, MannKind called a meeting yesterday of its data safety monitoring board (a committee of outside experts picked to keep an eye on danger signals with experimental drugs in human testing) and it concluded "that on the basis of the current information our trials could continue."
Page 1 of 3 | Next PageShow Entire Article
MNKD News & Analysis
DATA IS REAL-TIME EXCEPT NOTED WITH *
* DATA DELAYED AT LEAST 15 MINUTES